Read by QxMD icon Read

Cellular Oncology (Dordrecht)

Pinar Eser Ocak, Umut Ocak, Jiping Tang, John H Zhang
BACKGROUND: Caveolin-1 (cav-1) is the major structural protein of caveolae, the flask-shaped invaginations of the plasma membrane mainly involved in cell signaling. Today, cav-1 is believed to play a role in a variety of disease processes including cancer, owing to the variations of its expression in association with tumor progression, invasive behavior, metastasis and therapy resistance. Since first detected in the brain, a number of studies has particularly focused on the role of cav-1 in the various steps of brain tumorigenesis...
April 16, 2019: Cellular Oncology (Dordrecht)
Maschenka C A Balkenhol, Peter Bult, David Tellez, Willem Vreuls, Pieter C Clahsen, Francesco Ciompi, Jeroen A W M van der Laak
PURPOSE: The prognostic value of mitotic count for invasive breast cancer is firmly established. As yet, however, limited studies have been aimed at assessing mitotic counts as a prognostic factor for triple negative breast cancers (TNBC). Here, we assessed the prognostic value of absolute mitotic counts for TNBC, using both deep learning and manual procedures. METHODS: A retrospective TNBC cohort (n = 298) was used. The absolute manual mitotic count was assessed by averaging counts from three independent observers...
April 15, 2019: Cellular Oncology (Dordrecht)
Afsane Bahrami, Muhammed Majeed, Amirhossein Sahebkar
BACKGROUND: Epithelial-to-mesenchymal transition (EMT) is involved in tumor progression, invasion, migration and metastasis. EMT is a process by which polarized epithelial cells acquire motile mesothelial phenotypic features. This process is initiated by disassembly of cell-cell contacts through the loss of epithelial markers and replacement of these markers by mesenchymal markers. Reconstruction of the cytoskeleton and degradation of the tumor basement membrane ensures the spread of invasive malignant tumor cells to distant locations...
April 13, 2019: Cellular Oncology (Dordrecht)
Guillem Ramis, Ruth Villalonga-Planells, Margalida Serra-Sitjar, Marta Brell, Silvia Fernández de Mattos, Priam Villalonga
PURPOSE: Although EGFR activation is a hallmark of glioblastoma (GBM), anti-EGFR therapy has so far not yielded the desired effects. Targeting PI3K/Akt has been proposed as a strategy to increase the cellular sensitivity to EGFR inhibitors. Here we evaluated the contribution of FOXO3a, a key Akt target, in the response of GBM cells to EGFR inhibition. METHODS: FOXO3a activation was assessed by immunofluorescence and gene reporter assays, and by evaluating target gene expression using Western blotting and qRT-PCR...
April 13, 2019: Cellular Oncology (Dordrecht)
Alessandro Leonetti, Francesco Facchinetti, Roberta Minari, Alessio Cortellini, Christian D Rolfo, Elisa Giovannetti, Marcello Tiseo
BACKGROUND: Small-cell lung cancer (SCLC) is an aggressive disease with still limited therapeutic options. Despite being both a chemo- and radiation-sensitive malignancy, SCLC recurrence occurs in most cases and negatively impacts patients' prognosis. Over the last few years, a deeper understanding of SCLC molecular aberrations has led to the identification of Notch pathway deregulation as a crucial event in SCLC tumorigenesis, disease progression and chemoresistance. In particular, the delta-like protein 3 (DLL3), a Notch inhibitory ligand whose expression is directly related to the key neuroendocrine transcription factor ASCL1, was found to be expressed in ~85% of SCLCs, while it exhibits minimal to absent surface expression in normal lungs...
April 9, 2019: Cellular Oncology (Dordrecht)
Chai Phei Gan, Kin Kit Sam, Pei San Yee, Nur Syafinaz Zainal, Bernard Kok Bang Lee, Zainal Ariff Abdul Rahman, Vyomesh Patel, Aik Choon Tan, Rosnah Binti Zain, Sok Ching Cheong
PURPOSE: Oral squamous cell carcinoma (OSCC) is a challenging disease to treat. Up to 50% of OSCC patients with advanced disease develop recurrences. Elucidation of key molecular mechanisms underlying OSCC development may provide opportunities to target specific genes and, thus, to improve patient survival. In this study, we examined the expression and functional role of interferon transmembrane protein 3 (IFITM3) in OSCC development. METHODS: The expression of IFITM3 in OSCC and normal oral mucosal tissues was assessed by qRT-PCR and immunohistochemistry...
April 4, 2019: Cellular Oncology (Dordrecht)
In-Hyoung Yang, Ji-Youn Jung, Sung-Hyun Kim, Eun-Seon Yoo, Nam-Pyo Cho, Hakmo Lee, Jeong-Yeon Lee, Seong Doo Hong, Ji-Ae Shin, Sung-Dae Cho
PURPOSE: ABT-263 is a potent BH3 mimetic that possesses anticancer potential against various types of cancer. In general, this potential is due to its high binding affinity to anti-apoptotic proteins in the Bcl-2 family that disrupt sequestration of pro-apoptotic proteins. In the present study, we sought to identify an alternative regulatory mechanism responsible for ABT-263-mediated anticancer activity in human oral cancer. METHODS: We investigated the in vitro anti-cancer effects of ABT-263 using a trypan blue exclusion assay, Western blotting, DAPI staining, immunofluorescence staining, a live/dead assay, microarray-based expression profiling, and quantitative real-time PCR...
March 27, 2019: Cellular Oncology (Dordrecht)
Jianbing Huang, Yuan Li, Zhiliang Lu, Yun Che, Shouguo Sun, Shuangshuang Mao, Yuanyuan Lei, Ruochuan Zang, Ning Li, Sufei Zheng, Chengming Liu, Xinfeng Wang, Nan Sun, Jie He
PURPOSE: Hub genes are good molecular candidates for targeted cancer therapy. As yet, however, there is little information on the clinical implications and functional characteristics of hub genes in the development of non-small cell lung cancer (NSCLC). In this study, we set out to analyze the role of hub genes in NSCLC. METHODS: We performed weighted gene co-expression network analysis (WGCNA) to analyze gene networks during NSCLC development using transcriptomic data from normal, pre-cancer and cancer tissues...
March 18, 2019: Cellular Oncology (Dordrecht)
Ahmad Ghasemi, Jafar Saeidi, Mohsen Azimi-Nejad, Seyed Isaac Hashemy
BACKGROUND: Increasing evidence indicates that obesity is associated with tumor development and progression. Leptin is an adipocyte-related hormone with a key role in energy metabolism and whose circulating levels are elevated in obesity. The effect of leptin on cancer progression and metastasis and its underlying mechanisms are still unclear. Leptin can impact various steps in tumor metastasis, including epithelial-mesenchymal transition, cell adhesion to the extracellular matrix (ECM), and proteolysis of ECM components...
March 15, 2019: Cellular Oncology (Dordrecht)
Michal Hlavac, Annika Dwucet, Richard Eric Kast, Jens Engelke, Mike-Andrew Westhoff, Markus D Siegelin, Klaus-Michael Debatin, Christian Rainer Wirtz, Marc-Eric Halatsch, Georg Karpel-Massler
PURPOSE: Anti-apoptotic and pro-migratory phenotypes are hallmarks of neoplastic diseases, including primary brain malignancies. In this work, we examined whether reprogramming of the apoptotic and migratory machineries through a multi-targeting approach would induce enhanced cell death and enhanced inhibition of the migratory capacity of glioblastoma cells. METHODS: Preclinical testing and molecular analyses of combined inhibition of Bcl-2/Bcl-xL and RAC1 were performed in established, primary cultured and stem-like glioblastoma cell systems...
March 11, 2019: Cellular Oncology (Dordrecht)
Fereshteh Mehdipour, Mahboobeh Razmkhah, Zahra Faghih, Mandana Bagheri, Abdol-Rasoul Talei, Abbas Ghaderi
PURPOSE: The role of cytokine-producing B cells in antitumor immunity is mostly overlooked. In the present study, we investigated changes in B cell cytokine profiles in breast tumor-draining lymph nodes (TDLNs) during disease progression, and associations of these changes with prognostic indicators. METHODS: Flow cytometry was used to measure the expression of TNF-α, IL-10, TGF-β, IL-2 and IFN-γ in B cells from 42 axillary lymph nodes. The frequencies of IL-10+ and FoxP3+ T regulatory cells (Tregs) were also determined...
March 8, 2019: Cellular Oncology (Dordrecht)
Tessa P Sandberg, Iris Sweere, Gabi W van Pelt, Hein Putter, Louis Vermeulen, Peter J Kuppen, Rob A E M Tollenaar, Wilma E Mesker
PURPOSE: Lack of expression of the intestinal transcription factor CDX2 in colorectal cancer (CRC) identifies patients with a poor prognosis. This biomarker has previously been suggested to be prognostic in CRCs with a high stromal content based on mRNA expression data. We investigated the prognostic value of CDX2 expression in microsatellite stable CRC stratified by stromal content using microscopy-based techniques. METHODS AND RESULTS: The study included a cohort of 236 patients with stage I-IV CRC...
March 8, 2019: Cellular Oncology (Dordrecht)
Jae Young Hur, Hyeong Ryul Kim, Jung Yeon Lee, Sojung Park, Ji An Hwang, Woo Sung Kim, Shinkyo Yoon, Chang-Min Choi, Jin Kyung Rho, Jae Cheol Lee
PURPOSE: Despite the development of molecular targeted therapies, few advances have been made in the treatment of lung squamous cell carcinoma (SCC). SOX2 amplification is one of the most common genetic alterations in SCC. Here, we investigated the effects of THZ1, a potent cyclin-dependent kinase 7 (CDK7) inhibitor that plays a key role in gene transcription, in SCC. METHODS: Lung SCC-derived cell viabilities were assessed using a CCK-8 assay. SOX2 expression and RNAPII-CTD phosphorylation levels after THZ1 treatment were determined by Western blotting...
March 5, 2019: Cellular Oncology (Dordrecht)
Amin Jafari-Oliayi, Malek Hossein Asadi
BACKGROUND: Long non-coding RNAs (lncRNAs) are known as RNAs that do not encode proteins and that are more than 200 nucleotides in size. Previously, it has been found that LncRNAs play crucial roles in normal cellular processes, including proliferation and apoptosis. A growing body of evidence suggests that lncRNAs may also play regulatory roles in the initiation, progression and metastasis of various malignancies, including breast cancer. SNHG6 is a lncRNA that has previously been found to contribute to the initiation and progression of hepatocellular and gastric carcinomas...
March 2, 2019: Cellular Oncology (Dordrecht)
Simin Ahmadvand, Zahra Faghih, Mehdi Montazer, Akbar Safaei, Maral Mokhtari, Peyman Jafari, Abdol-Rasoul Talei, Sedigheh Tahmasebi, Abbas Ghaderi
PURPOSE: In recent years, the prognostic/predictive significance of tumor infiltrating lymphocytes (TILs) has become a topic of interest. Here, we aimed to evaluate the prognostic significance of CD3+, CD8+, CD45RO+ and Foxp3+ TILs in breast cancer, as well as the relation of these markers to other clinicopathological features of this disease. METHODS: FFPE tumor samples from 94 females with invasive ductal carcinoma of the breast were retrospectively selected and immunohistochemically assessed for CD3, CD8, CD45RO and Foxp3 expression...
March 1, 2019: Cellular Oncology (Dordrecht)
Oscar G F Geessink, Alexi Baidoshvili, Joost M Klaase, Babak Ehteshami Bejnordi, Geert J S Litjens, Gabi W van Pelt, Wilma E Mesker, Iris D Nagtegaal, Francesco Ciompi, Jeroen A W M van der Laak
PURPOSE: Tumor-stroma ratio (TSR) serves as an independent prognostic factor in colorectal cancer and other solid malignancies. The recent introduction of digital pathology in routine tissue diagnostics holds opportunities for automated TSR analysis. We investigated the potential of computer-aided quantification of intratumoral stroma in rectal cancer whole-slide images. METHODS: Histological slides from 129 rectal adenocarcinoma patients were analyzed by two experts who selected a suitable stroma hot-spot and visually assessed TSR...
March 1, 2019: Cellular Oncology (Dordrecht)
Julieta Afonso, Tatiana Pinto, Susana Simões-Sousa, Fernando Schmitt, Adhemar Longatto-Filho, Céline Pinheiro, Herlander Marques, Fátima Baltazar
PURPOSE: Increased glycolytic activity with accumulation of extracellular lactate is regarded as a hallmark of cancer. In lymphomas, FDG-PET has undeniable diagnostic and prognostic value, corroborating that these tumours are avid for glucose. However, the role of glycolytic metabolism-related molecules in lymphoma is not well known. Here, we aimed to evaluate the clinical and prognostic significance of a panel of glycolytic metabolism-related molecules in primary non-Hodgkin lymphomas (NHL) and to test in vitro the putative therapeutic impact of lactate transport inhibition...
February 21, 2019: Cellular Oncology (Dordrecht)
Xiqiao Zhou, Ailin Zhu, Xinbin Gu, Guiqin Xie
BACKGROUND: Hepatocellular carcinoma (HCC) is an aggressive malignancy. In HCC, mitogen-activated protein kinase (MAPK) signaling is overactivated. The MAPK kinase (MEK) inhibitor trametinib has been approved to treat several types of advanced cancers with a BRAF mutation. Herein, we examined whether trametinib has efficacy against HCC. METHODS: The effects of trametinib on cell viability, proliferation and tumor growth were assessed in HCC-derived cell lines and mouse xenograft models...
February 20, 2019: Cellular Oncology (Dordrecht)
Ouissam Ayachi, Meltem Barlin, Pia Nora Broxtermann, Hamid Kashkar, Cornelia Mauch, Paola Zigrino
BACKGROUND: The X-linked inhibitor of apoptosis (XIAP) is a potent cellular inhibitor of apoptosis, based on its unique capability to bind and to inhibit caspases. However, XIAP is also involved in a number of additional cellular activities independent of its caspase inhibitory function. The aim of this study was to investigate whether modulation of XIAP expression affects apoptosis-independent functions of XIAP in melanoma cells, restores their sensitivity to apoptosis and/or affects their invasive and metastatic capacities...
February 18, 2019: Cellular Oncology (Dordrecht)
María Julia Lamberti, Mandy Rettel, Jeroen Krijgsveld, Viviana Alicia Rivarola, Natalia Belén Rumie Vittar
PURPOSE: Previous analyses of the tumor microenvironment (TME) have resulted in a concept that tumor progression may depend on interactions between cancer cells and its surrounding stroma. An important aspect of these interactions is the ability of cancer cells to modulate stroma behavior, and vice versa, through the action of a variety of soluble mediators. Here, we aimed to identify soluble factors present in the TME of colorectal cancer cells that may affect relevant pathways through secretome profiling...
February 12, 2019: Cellular Oncology (Dordrecht)
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"